BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, Schwenoha L, Datz L, Balcar L, Semmler M, Stickel F, Niederseer D, Aigner E, Datz C. Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality. J Clin Endocrinol Metab 2021:dgab339. [PMID: 33982065 DOI: 10.1210/clinem/dgab339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Taniguchi K, Ikeda Y, Nagase N, Tsuji A, Kitagishi Y, Matsuda S; Department of Food Science and Nutrition, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan. . AIMSBOA 2021;8:243-56. [DOI: 10.3934/bioeng.2021021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci 2021;22:11629. [PMID: 34769060 DOI: 10.3390/ijms222111629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
5 Tao ZY, Zeng J. Role of non-alcoholic fatty liver disease in development of cardiovascular disease. Shijie Huaren Xiaohua Zazhi 2022; 30(3): 136-139 [DOI: 10.11569/wcjd.v30.i3.136] [Reference Citation Analysis]
6 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. Int J Mol Sci 2021;22:6949. [PMID: 34203309 DOI: 10.3390/ijms22136949] [Reference Citation Analysis]
7 Chen Y, Ma L, Ge Z, Pan Y, Xie L. Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome. Front Mol Biosci 2022;9:888194. [DOI: 10.3389/fmolb.2022.888194] [Reference Citation Analysis]
8 Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, Hur KY, Kim JH. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol 2021;20:197. [PMID: 34583706 DOI: 10.1186/s12933-021-01374-8] [Reference Citation Analysis]